The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models

References

• Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010; 16:1701 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-09-1692; PMID: 20197482
   PubMed Web of Science ®Google Scholar
• Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 2010; 16:497 - 508; http://dx.doi.org/10.1158/1078-0432.CCR-09-1929; PMID: 20068083
   PubMed Web of Science ®Google Scholar
• Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000; 156:1253 - 61; http://dx.doi.org/10.1016/S0002-9440(10)64996-6; PMID: 10751351
   PubMed Web of Science ®Google Scholar
• Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. [erratum appears in Cancer Res 2002 Aug;62(15):4532] Cancer Res 2002; 62:2890 - 6; PMID: 12019169
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Cho S, Browning B, Zheng TS, Lincecum JM, Wang MZ, et al. Tweak induces mammary epithelial branching morphogenesis. Oncogene 2005; 24:2613 - 24; http://dx.doi.org/10.1038/sj.onc.1208208; PMID: 15735761
   PubMed Web of Science ®Google Scholar
• Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003; 162:1313 - 21; http://dx.doi.org/10.1016/S0002-9440(10)63927-2; PMID: 12651623
   PubMed Web of Science ®Google Scholar
• Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, et al. Transcriptional profiling suggests that Barrett’s metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006; 25:3346 - 56; http://dx.doi.org/10.1038/sj.onc.1209357; PMID: 16449976
   PubMed Web of Science ®Google Scholar
• Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 2008; 6:725 - 34; http://dx.doi.org/10.1158/1541-7786.MCR-08-0005; PMID: 18505918
   PubMed Web of Science ®Google Scholar
• Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272:32401 - 10; http://dx.doi.org/10.1074/jbc.272.51.32401; PMID: 9405449
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs 2011; 3:362 - 75; http://dx.doi.org/10.4161/mabs.3.4.16090; PMID: 21697654
   PubMed Web of Science ®Google Scholar
• Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, et al. Multiple pathways of TWEAK-induced cell death. J Immunol 2002; 168:734 - 43; PMID: 11777967
   PubMed Web of Science ®Google Scholar
• Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, et al. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 2003; 170:341 - 8; PMID: 12496418
   PubMed Web of Science ®Google Scholar
• Schneider P, Schwenzer R, Haas E, Mühlenbeck F, Schubert G, Scheurich P, et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol 1999; 29:1785 - 92; http://dx.doi.org/10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; PMID: 10382740
   PubMed Web of Science ®Google Scholar
• Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008; 182:171 - 84; http://dx.doi.org/10.1083/jcb.200801010; PMID: 18606850
   PubMed Web of Science ®Google Scholar
• Wilson CA, Browning JL. Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis. Cell Death Differ 2002; 9:1321 - 33; http://dx.doi.org/10.1038/sj.cdd.4401107; PMID: 12478469
   PubMed Web of Science ®Google Scholar
• Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res 2006; 66:9617 - 24; http://dx.doi.org/10.1158/0008-5472.CAN-06-0217; PMID: 17018619
   PubMed Web of Science ®Google Scholar
• Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003; 21:3526 - 34; http://dx.doi.org/10.1200/JCO.2003.09.037; PMID: 12972530
   PubMed Web of Science ®Google Scholar
• Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 2010; 9:2582 - 92; http://dx.doi.org/10.1158/1535-7163.MCT-10-0370; PMID: 20660600
   PubMed Web of Science ®Google Scholar
• Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12:4652 - 61; http://dx.doi.org/10.1158/1078-0432.CCR-06-0113; PMID: 16899615
   PubMed Web of Science ®Google Scholar